Logo
x

Search

Subscribe Now

Acceptance

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin) to Treat HFpEF

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin...

  • November 12, 2021
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in...

  • October 15, 2021
Regeneron Reports the US FDA's Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19

Regeneron Reports the US FDA's Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19

  • October 14, 2021
Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration

Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related M...

  • October 5, 2021
BeiGene and Novartis Report the US FDA's Acceptance of BLA for Tislelizumab to Treat Esophageal Squamous Cell Carcinoma

BeiGene and Novartis Report the US FDA's Acceptance of BLA for Tislelizumab to Treat Esophageal Squamous Cell Carcinoma

  • September 13, 2021
Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency

Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency

  • August 18, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.